A dose-ranging study of the pharmacodynamic effects of BMS-562086 [pexacerfont] on gastrointestinal transit in women with diarrhea-predominant irritable bowel syndrome
Phase of Trial: Phase II
Latest Information Update: 17 May 2008
At a glance
- Drugs Pexacerfont (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacodynamics
- 20 Mar 2008 Status changed from in progress to completed, in accordance with clinicaltrials.gov.
- 10 Sep 2007 Status changed from recruiting to in progress.
- 09 Jan 2007 Status change